PMID- 32208487

OWN - NLM
STAT- In-Data-Review
LR - 20200327
IS - 2473-9537 (Electronic)
IS - 2473-9529 (Linking)
VI - 4
IP - 6
DP - 2020 Mar 24
TI - Phase 2 trial of montelukast for prevention of pain in sickle cell disease.
PG - 1159-1165
LID - 10.1182/bloodadvances.2019001165 [doi]
AB - Cysteinyl leukotrienes (CysLTs) are lipid mediators of inflammation. In
patients
with sickle cell disease (SCD), levels of CysLTs are increased compared with
controls and associated with a higher rate of hospitalization for pain. We
tested
the hypothesis that administration of the CysLT receptor antagonist
montelukast
would improve SCD-related comorbidities, including pain, in adolescents and
adults with SCD. In a phase 2 randomized trial, we administered montelukast
or
placebo for 8 weeks. The primary outcome measure was a >30% reduction in
soluble
vascular cell adhesion molecule 1 (sVCAM), a marker of vascular injury.
Secondary
outcome measures were reduction in daily pain, improvement in pulmonary
function,
and improvement in microvascular blood flow, as measured by laser Doppler
velocimetry. Forty-two participants with SCD were randomized to receive
montelukast or placebo for 8 weeks. We found no difference between the
montelukast and placebo groups with regard to the levels of sVCAM, reported
pain,
pulmonary function, or microvascular blood flow. Although montelukast is an
effective treatment for asthma, we did not find benefit for SCD-related
outcomes.
This clinical trial was registered at www.clinicaltrials.gov as #NCT01960413.
CI - (c) 2020 by The American Society of Hematology.
FAU - Field, Joshua J
AU - Field JJ
AD - Medical Sciences Institute, Versiti Wisconsin, Milwaukee, WI.
AD - Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.
FAU - Kassim, Adetola
AU - Kassim A
AD - Department of Medicine, Vanderbilt University School of Medicine, Nashville,
TN.
FAU - Brandow, Amanda
AU - Brandow A
AD - Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI.
FAU - Embury, Stephen H
AU - Embury SH
AD - Vanguard Therapeutics, Inc., Half Moon Bay, CA; and.
FAU - Matsui, Neil
AU - Matsui N
AD - Vanguard Therapeutics, Inc., Half Moon Bay, CA; and.
FAU - Wilkerson, Karina
AU - Wilkerson K
AD - Department of Medicine, Vanderbilt University School of Medicine, Nashville,
TN.
FAU - Bryant, Valencia
AU - Bryant V
AD - Department of Pediatrics, Vanderbilt University School of Medicine,
Nashville,
TN.
FAU - Zhang, Liyun
AU - Zhang L
AD - Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI.
FAU - Simpson, Pippa
AU - Simpson P
AD - Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI.
FAU - DeBaun, Michael R
AU - DeBaun MR
AD - Department of Medicine, Vanderbilt University School of Medicine, Nashville,
TN.
AD - Department of Pediatrics, Vanderbilt University School of Medicine,
Nashville,
TN.
LA - eng
SI - ClinicalTrials.gov/NCT01960413
PT - Journal Article
PL - United States
TA - Blood Adv
JT - Blood advances
JID - 101698425
SB - IM
PMC - PMC7094028
EDAT- 2020/03/26 06:00
MHDA- 2020/03/26 06:00
CRDT- 2020/03/26 06:00
PHST- 2019/11/13 00:00 [received]
PHST- 2020/01/28 00:00 [accepted]
PHST- 2020/03/26 06:00 [entrez]
PHST- 2020/03/26 06:00 [pubmed]
PHST- 2020/03/26 06:00 [medline]
AID - 452752 [pii]
AID - 10.1182/bloodadvances.2019001165 [doi]
PST - ppublish
SO - Blood Adv. 2020 Mar 24;4(6):1159-1165. doi: 10.1182/bloodadvances.2019001165.